CN110368417A - Gorgon fruit extract is in the application for inhibiting the performance of ICAM-1 gene - Google Patents
Gorgon fruit extract is in the application for inhibiting the performance of ICAM-1 gene Download PDFInfo
- Publication number
- CN110368417A CN110368417A CN201810324648.2A CN201810324648A CN110368417A CN 110368417 A CN110368417 A CN 110368417A CN 201810324648 A CN201810324648 A CN 201810324648A CN 110368417 A CN110368417 A CN 110368417A
- Authority
- CN
- China
- Prior art keywords
- gorgon fruit
- composition
- fruit extract
- icam
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 55
- 244000268590 Euryale ferox Species 0.000 title claims abstract description 53
- 235000006487 Euryale ferox Nutrition 0.000 title claims abstract description 51
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 51
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 title description 4
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 230000002265 prevention Effects 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 21
- 210000004204 blood vessel Anatomy 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- 206010034464 Periarthritis Diseases 0.000 claims description 15
- 208000025887 endotheliitis Diseases 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 101150084750 1 gene Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000035790 physiological processes and functions Effects 0.000 abstract description 3
- 239000002158 endotoxin Substances 0.000 description 16
- 229920006008 lipopolysaccharide Polymers 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000003606 umbilical vein Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000001497 healthy food Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- -1 hypotensor Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000014594 pastries Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Botany (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
It is a kind of using Gorgon fruit extract in the purposes for manufacturing a composition, wherein the composition is for inhibitingICAM‑1Gene performance, thus reach treatment, prevention or adjust withICAM‑1The disease of gene-correlation or the effect of physiological function.
Description
Technical field
Application of the present invention about Gorgon fruit extract, including use the extract in treatment, prevention or adjust withICAM-1
The disease or physiological function of gene-correlation, especially with the extract in treatment and/or prevention cardiovascular disease.
Background technique
In recent years, incidence of the cardiovascular disease in various countries remains high repeatedly, and lethality is high, about causes 1700 every year
Ten thousand people are dead.It is known that the generation of cardiovascular disease is related to blood vessel endothelium inflammation, wherein being again most common with arteriosclerosis
Cardiovascular disease.So-called arteriosclerosis refers to that the cholesterol in blood vessel builds up the formation atherosclerotic spot on vascular wall
Block leads to vessel wall thickening, is hardened, follows the string, so that blood smooth can not flow through the pathological condition of blood vessel, may cause it
His cardiovascular disease (such as ischemic heart disease, apoplexy and Peripheral arteries obstruction etc.).It is known that suffering from hypertension, hyperlipidemia, sugar
The patients of diseases such as urine disease have smoking or the habit person that drinks, lack sporter and overweight people, are all arteriosclerosis
High-risk populations.
At present clinically, the drugs such as hypotensor, hypoglycemic agent, hypolipidemic or anticoagulant are often used to artery congee
The high-risk populations of shape hardening or patient control or treat.When serious when the patient the case where, then heparin tube Endarterectomy or
Endovascular stent is placed art etc. and is surgically treated, but aforementioned operative treatment mode has come under invasive procedures, postoperative
Restore slower, therefore, the drug or method of the cardiovascular diseases such as arteriosclerosis can effectively be treated and/or be improved to Persisting exploitation
It is having its essential and urgency.
It is known thatICAM-1The performance amount increase of gene will cause blood vessel endothelium inflammation, and then lead to the hair of cardiovascular disease
It is raw.In addition, research also show, the generation of breast cancer and sticky articular capsulitis withICAM-1The excessive performance of gene is related, this can
See, for example: Caridad Rosette et al. is published in 2005 document, Role of ICAM1 in invasion of
Human breast cancer cells and Yang-Soo Kim et al. is published in 2013 document,
Intercellular Adhesion Molecule-1 (ICAM-1, CD54) Is Increased in Adhesive
Capsulitis, the full text of these documents are simultaneously for reference in herein.
Therefore, if can be effectively suppressedICAM-1The performance of gene can reach and inhibit blood vessel endothelium inflammation, treatment cardiovascular
Disease, prevention cardiovascular disease, treatment breast cancer, prevention breast cancer, treatment sticky articular capsulitis, prevention sticky articular capsulitis,
It helps to maintain blood vessel elasticity and assists the effect of joint care.
Inventor is the study found that Gorgon fruit extract has inhibitionICAM-1The effect of the performance of gene, therefore can be used for
Blood vessel endothelium inflammation, treatment cardiovascular disease, prevention cardiovascular disease, treatment breast cancer, prevention breast cancer, treatment sticky is inhibited to close
Condyle is scorching, prevention sticky articular capsulitis, helps to maintain blood vessel elasticity and/or auxiliary joint care.
Summary of the invention
A purpose of the invention, be to provide it is a kind of using Gorgon fruit extract in the purposes for manufacturing a composition, wherein should
Composition is for inhibitingICAM-1Gene performance.Preferably, the Gorgon fruit extract is the polar solvent extract object of Gorgon fruit, the polarity
Solvent is selected from following group: water, C1-C4 alcohols and combination above-mentioned.
Provided composition can be a medical composition or a food compositions according to the present invention, wherein the basis
Medical composition provided by the present invention can be used for inhibiting blood vessel endothelium inflammation, treatment cardiovascular disease, prevention cardiovascular disease,
Treat breast cancer, prevention breast cancer, treatment sticky articular capsulitis (adhesive capsulitis) and prevention sticky joint capsule
At least one scorching.For example, this according to the present invention provided by medical composition can be used for treat and/or prevention of arterial congee
Shape hardening.
In addition, this according to the present invention provided by food compositions can be used for helping to maintain blood vessel elasticity and auxiliary joint
At least one of health care.
It is another object of the present invention to provide a kind of inhibitionICAM-1The method of gene performance, it includes have to need to one
The individual one a effective amount of Gorgon fruit extract of administering wanted.The method of the present invention can be used for it is below at least one: inhibit blood vessel endothelium
Inflammation, treatment cardiovascular disease, prevention cardiovascular disease, treatment breast cancer, prevention breast cancer, treatment sticky articular capsulitis, prevention
Sticky articular capsulitis, help maintain blood vessel elasticity and auxiliary joint care.For example, this according to the method for the present invention may be used
For treatment and/or prevention of arterial atherosclerosis.According to the method for the present invention, used Gorgon fruit extract can be above-mentioned
The form of composition administer to the individual in need.
Detailed technology content and part specific embodiment of the invention, will be described in the following contents, for the present invention
Feature of the invention is illustrated in one of ordinary skill in the art accordingly.
Detailed description of the invention
Fig. 1 shows Gorgon fruit extract of the present invention in inhibitionICAM-1The effect of gene performance, wherein " control group " is in not
Cultivate 3 hours human umbilical vein's endothelial cells in culture solution containing LPS and Gorgon fruit extract, " LPS group " is in containing LPS
But cultivate 3 hours human umbilical vein's endothelial cells in the culture solution without Gorgon fruit extract, " extract group " is then in containing
Having human umbilical vein's endothelial cell for cultivating in the culture solution of LPS and Gorgon fruit extract 3 hours, (# indicates have significantly with LPS group
Difference, p < 0.05).
Specific embodiment
Part specific embodiment according to the present invention explained below；But under without departing substantially from spirit of that invention, the present invention
It can be practiced with a variety of various forms of embodiments, it is specific old that the scope of the present invention should not be interpreted as being limited to specification institute
What state or claims were defined.
Unless in addition Wen Zhongyou illustrates, in this manual (especially in detail in the claims) used in " one ",
"the" and similar term are interpreted as comprising odd number and plural form；So-called " treatment " it is straight to be not necessarily to be construed as one individual for the treatment of
Restore to complete, and should include that the progression of disease of an individual or symptom are maintained to a substantially static degree, increase by one
The regeneration rate of body, the seriousness for improving a specific patient's condition or the life quality for improving a patient；So-called " prevention " refers to inhibition
Or it prevents the breaking-out of a specific patient's condition or maintains the good health state of sensitive individual or establish tolerance of the individual to disease
Property；So-called " adjusting " refer to positive regulation (including induction, stimulation and enhancing) or negative regulation (including inhibit and weaken) with
Make normal condition of the individual towards the physiological function；So-called " individual " refers to mammal, which can be the mankind
Or non-human animal.
Gorgon fruit (Euryale seed, or " qian shi ") is the seed of Nymphaeceae Gorgon euryale platymiscium.Inventor grinds
Study carefully discovery, Gorgon fruit extract, which has, to be inhibitedICAM-1The effect of gene performance.Therefore, the present invention about use Gorgon fruit extract with
InhibitICAM-1The application of gene performance, this includes: to be used using Gorgon fruit extract in the purposes for preparing a composition and one
The method of the Gorgon fruit extract, comprising administering an a effective amount of Gorgon fruit extract to an individual in need, to inhibitICAM-1
Gene performance.
Used Gorgon fruit extract according to the present invention, can be provided by extraction process.In specific words, the present invention is adopted
Gorgon fruit extract can be provided by the inclusion of the operation of following steps :(a) Gorgon fruit be extracted with an extractant, to provide one
Extract liquor；(b) centrifugal treating is carried out to the extract liquor, takes supernatant to be filtered, to provide a filtrate；(c) to the filtrate into
Row is concentrated under reduced pressure, to obtain a Gorgon fruit extract.
In step (a), which is a polar solvent, and the polar solvent can be water, alcohol (such as C1-C4
Alcohol), or combinations thereof.In addition, the dosage of extractant has no specifically limited, generalling use can be with the dosage of raw material dispersion.Citing
Yan Zhi can use extractant: Gorgon fruit=1 ~ 20:1 volume ratio dosage in step (a).In a specific implementation of the invention
In mode, with extractant: Gorgon fruit=10:1 volume ratio dosage carries out the extraction of step (a).
In step (a), it is visual used by extractant select suitable extraction time.To use water as extraction
Solvent, and extractant: for the volume ratio of Gorgon fruit is about 10 ~ 20:1, usually extraction lasts 0.5 ~ 2 hour.In addition, visually needing
To be aided with one or more other operations such as heating, cooling, stirring, ultrasonic prior to or just when carrying out step (a), with
Improve effect of extracting.For example, in the embodiment of the invention, it is stirred operation before Yu Jinhang step (a),
And step (a) is carried out under 85 °C, last 0.5 hour.To reach maximum extraction benefit as far as possible, optionally, can in into
Before row step (b), Gorgon fruit is carried out with identical or different extractant to repeat extraction, and merge and repeatedly extract resulting extraction
Liquid is taken to provide the extract liquor for carrying out step (b)；Also it may be repeated step (b).
In step (c), temperature when reduced pressure can be adjusted, optionally to avoid the effective component in Gorgon fruit extract
Denaturation.For example, the reduced pressure of step (c) can be carried out, in 45 to 70 °C to maintain effective component in Gorgon fruit extract
Stability.In the embodiment of the invention, the reduced pressure of step (c) is carried out in 55 to 65 °C to provide required Gorgon euryale
Real extract.
Provided composition is a medical composition or a food compositions according to the present invention.Wherein, according to the present invention
Provided medical composition can be used for it is below at least one: inhibit blood vessel endothelium inflammation, treatment cardiovascular disease, prevention the heart
Vascular diseases, treatment breast cancer, prevention breast cancer, treatment sticky articular capsulitis and prevention sticky articular capsulitis.Wherein, the heart
Vascular diseases refer in particular to arteriosclerosis.Provided food compositions according to the present invention can be used for below at least one
Person: help maintains blood vessel elasticity and auxiliary joint care.
According to the present invention provided medical composition can in it is any it is suitable in the form of, have no it is specifically limited, depending on desired
Purposes and be in corresponding suitable dosage form.For example, but not limited to this, the medical composition can take orally or it is non-by oral administration
The dosing mode of (such as: percutaneous, intravenous injection or subcutaneous injection) is applied on individual in need.Wherein, depending on use form
And depending on purposes, suitable carrier can be selected to provide the medical composition, wherein the carrier includes excipient, diluent, auxiliary
Auxiliary agent, absorption delaying agent, disintegrating agent, solubilizer, emulsifier, antioxidant, adhesive, bonding agent, tackifier, divides stabilization agent
Powder, suspending agent, lubricant, hygroscopic agent etc..
Be suitable for for oral dosage form, in the medical composition provided by according to the present invention can containing it is any will not
Benefit influences the pharmaceutically acceptable carrier of the be intended to benefit of active constituent (that is, Gorgon fruit extract), such as: water, saline solution, Portugal
Grape sugar (dextrose), glycerol, ethyl alcohol or its analog, cellulose, starch, sugared bentonite (sugar bentonite) and preceding
The combination stated.Using any suitable method, the dosage form which is suitable for oral administration medicine supplying is provided, such as: ingot
Agent (such as sugar-coat ingot), pill, capsule, granule, powder, liquid extract, solution, syrup, suspension agent, tincture etc..
It is suitable for for the dosage form percutaneously administered, provided medical composition can be in for direct external application according to the present invention
Patch, lotion, creams, gel (such as hydrogel), paste (such as dispersion cream, ointment), spray or solution are (such as outstanding
Supernatant liquid) etc. forms, but not limited to this.
It, then can be in provided doctor according to the present invention as the injection or drop dosage form for being suitable for subcutaneous or intravenous injection
Contain one or more such as isotonic solutions, salt buffer (such as phosphate buffer or Citrate buffer in drug composition
Liquid), solubilizer, emulsifier, the ingredients such as 5% sugar juice and other carriers, with venoclysis liquid, emulsion venoclysis liquid, dry
The dosage forms such as powder injection, suspension injection or dry powder suspension injection provide the medical composition.Alternatively, by the medicinal combination
Object is prepared into solid before an injection, and the dosage form to dissolve in other solution or suspension or emulsifiable dosage form provide the note
Preceding solid is penetrated, and in administering to before individual in need, solid before the injection is dissolved in other solution or suspension or is incited somebody to action
It is emulsified, to provide desired injection.
According to the present invention provided medical composition can once a day, one day repeatedly or a few days one inferior different throws
The application of medicine frequency, it is different depending on the demand of administering individual, age, weight and healthy condition shape.In provided medicine according to the present invention
In composition, visual practical application request adjusts content ratio of the Gorgon fruit extract in composition.In addition, the medicinal combination
Object optionally can separately contain one or more other active components (such as hypolipidemic, hypotensor and anticoagulant etc.), Huo Zheyu
Drug combination containing one or more other active components the effect of to further strengthen the medical composition or increases preparation and matches
The use flexibly and allotment degree of side, as long as the other active components are to the effect of inventive compound (that is, Gorgon fruit extract)
Benefit is not adversely influenced.
Optionally, suitable dosage can separately be contained in provided medical composition or food compositions according to the present invention
Additive, such as the suitable sense of the mouth of the medical composition or food compositions when taking and the seasoning of visual experience can be improved
Agent, toner, colorant etc., and the stability of the medical composition or food compositions and the buffering of storage characteristics can be improved
Agent, preservative agent, preservative, antibacterial agent, antifungal agent etc..
Provided food compositions can be healthy food, health food, functional food, nutrition benefit according to the present invention
Fill food or food of special nutrients, and can be made into for example dairy products, meat packing product, Bread and Pastries, pastries, biscuit, mouth containing ingot,
The products such as capsule, juice, teas, sports drink, nutritious drink, but not limited to this.Preferably, being provided according to the present invention
Food compositions provided in the form of healthy food.
Provided healthy food, health food, functional food, nutrient supplement food and special dietary according to the present invention
Food can once a day, one day repeatedly or the inferior different frequency of a few days one is edible, age of view administering individual, weight and be good for
Health situation and it is different.Also the needs of specific group, healthy food, health food, machine provided by adjustment according to the present invention can be directed to
Can property food, in nutrient supplement food and food of special nutrients Gorgon fruit extract content, for example, adjusting to should take daily
Amount.
For healthy food, health food provided by according to the present invention, functional food, nutrient supplement food and/or
Food of special nutrients, can in its outer packing mark suggest usage amount, specific group (such as paralytic, cardiac and
Pregnant woman etc.) using standard and condition or with other food or the suggestion item etc. taken jointly of medicine, with sharp user in nothing
Voluntarily taken under doctor, pharmacist or related office-bearer guidance and without security concerns.In provided food group according to the present invention
It closes in object, aspect and relevant application in relation to the Gorgon fruit extract, as the above description.
The present invention also provides a kind of inhibitionICAM-1The method of gene performance, it includes to an individual administering one in need
A effective amount of Gorgon fruit extract.Preferably, this method to treat, prevent or adjust withICAM-1The disease or life of gene-correlation
Function is managed, particularly for treating and/or preventing cardiovascular disease.According to the method for the present invention, used Gorgon fruit extraction
Object can be administered in the form of a composition to the individual in need.Administering aspect, administering approach, administering in relation to the composition
Form, frequency of administration and relevant application, as the above description.
The present invention is now illustrated further with the following example.Wherein these embodiments are merely provided as illustrating, rather than
To limit the scope of the invention.The scope of the present invention is subject to claims.
Embodiment
In following embodiment, used material source is as follows:
1. Gorgon fruit: being purchased from the Taiwan four seasons organic international corporation.
2. human umbilical vein's endothelial cell (human umbilical vein endothelial cell, HUVEC):
Purchased from BCRC, product number H-UV001.
3. EC culture medium: M200 culture medium (being purchased from Gibco, product number M-200-500)+10% LSGS(Low
Serum Growth Supplement is purchased from Gibco, product number S-003-10).
4. LPS(Lipopolysaccharides): it is purchased from Gibco, product number 00-4976.
5. RNA extracts set group (RNA Extraction Kit): being purchased from GENEmark.
6. reverse transcriptase (SuperScript III Reverse Transcriptase): being purchased from Invitrogen.
7. KAPA SYBR FAST qPCR set group: being purchased from KAPA Biosystems.
8. Step One Plus instrument: being purchased from ABI.
Prepare embodiment]
The preparation of Gorgon fruit extract
Processing is performed the following operation to Gorgon fruit, to provide Gorgon fruit extract:
1. Gorgon fruit (not removing the peel) is mixed (volume ratio of Gorgon fruit and water is 1:10) with water, and extracted, is lasted under 85 °C
0.5 hour, to provide an extract liquor；
2. the extract liquor of step 1 is taken to be centrifuged, after taking supernatant, it is filtered with strainer, to provide a filtrate；
3. the filtrate of step 2 is concentrated under reduced pressure under 55 to 65 °C, to provide a Gorgon fruit extract.
Embodiment 1: Gorgon fruit extract of the present invention is in inhibitionICAM-1The effect of gene performance
Human umbilical vein's endothelial cell is inoculated in 6- porose disc (every 1 x 10 of hole5A cell) in, it, will be thin after culture 1 hour
Born of the same parents are divided into control group, LPS group and extract group, and are cultivated respectively with following culture medium, last 3 hours:
1. control group: EC culture medium；
2. LPS group: the EC culture medium containing 1 mcg/ml LPS；
3. extract group: being extracted containing 1 mcg/ml LPS and 0.5 mg/ml by the Gorgon fruit that [preparation embodiment B] is obtained
The EC culture medium of object.
Thereafter, above-mentioned group of cells is collected respectively, RNA extraction is carried out with RNA extraction set group, then should with reverse transcriptase
RNA reverse transcription is cDNA.Then, using ABI Step One Plus instrument and KAPA SYBR FAST qPCR set group to aforementioned
CDNA carry out qPCR(quantitative polymerase chain reaction), to detect group of cellsICAM-1
The performance amount of gene.
Above-mentioned experiment carries out three and repeats, after which is averaged, then on the basis of the result of control group (that is,
The gene performance amount of control group is set as 1 times), calculate the gene relative performance amount of LPS group and extract group.As a result it is shown in figure
1。
As shown in Figure 1, compared to control group, LPS groupICAM-1Gene performance amount significantly rises, and display LPS really may be used
To induce blood vessel endothelium inflammation.Compared to LPS group, extract groupICAM-1Gene performance amount is then remarkably decreased, and shows this hair
Bright Gorgon fruit extract can significantly reduce caused by LPSICAM-1Gene performance amount rises.Aforementioned result shows, Gorgon fruit of the present invention
Extract can be effectively suppressed reallyICAM-1Gene performance amount, thus can be used for inhibiting blood vessel endothelium inflammation, treatment cardiovascular disease,
Prevention cardiovascular disease, prevention breast cancer, treatment sticky articular capsulitis, prevention sticky articular capsulitis, helps to tie up at treatment breast cancer
Hold blood vessel elasticity and auxiliary joint care.
Claims (6)
1. it is a kind of using Gorgon fruit extract in the purposes for manufacturing a composition, it is characterised in that: the composition is for inhibitingICAM- 1Gene performance.
2. purposes as described in claim 1, it is characterised in that: the Gorgon fruit extract is the polar solvent extract object of Gorgon fruit, should
Polar solvent is selected from following group: water, C1-C4 alcohols and combination above-mentioned.
3. the purposes as described in any one of claims 1 to 2, it is characterised in that: the composition is a medical composition, is used for
Inhibit blood vessel endothelium inflammation.
4. the purposes as described in any one of claims 1 to 2, it is characterised in that: the composition is a medical composition, is used for
It is below at least one: treatment cardiovascular disease, prevention cardiovascular disease, treatment breast cancer, prevention breast cancer, treatment sticky joint
Capsulitis and prevention sticky articular capsulitis.
5. purposes as claimed in claim 4, it is characterised in that: the cardiovascular disease is arteriosclerosis.
6. the purposes as described in any one of claims 1 to 2, it is characterised in that: the composition is a food compositions, is used for
It helps to maintain at least one of blood vessel elasticity and auxiliary joint care.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810324648.2A CN110368417A (en) | 2018-04-12 | 2018-04-12 | Gorgon fruit extract is in the application for inhibiting the performance of ICAM-1 gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810324648.2A CN110368417A (en) | 2018-04-12 | 2018-04-12 | Gorgon fruit extract is in the application for inhibiting the performance of ICAM-1 gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110368417A true CN110368417A (en) | 2019-10-25 |
Family
ID=68243524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810324648.2A Pending CN110368417A (en) | 2018-04-12 | 2018-04-12 | Gorgon fruit extract is in the application for inhibiting the performance of ICAM-1 gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110368417A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201943423A (en) * | 2018-04-10 | 2019-11-16 | 大江生醫股份有限公司 | Uses of euryale seed extract in inhibiting expression of ICAM-1 gene |
-
2018
- 2018-04-12 CN CN201810324648.2A patent/CN110368417A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201943423A (en) * | 2018-04-10 | 2019-11-16 | 大江生醫股份有限公司 | Uses of euryale seed extract in inhibiting expression of ICAM-1 gene |
Non-Patent Citations (1)
| Title |
|---|
| 陈志宏等: "芡实酒对小白鼠主要生理生化指标的影响", 《食品科技》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018145664A1 (en) | Anti-fatigue composition for use in improving endurance performance | |
| CN106387900A (en) | Composition for regulating blood lipid, blood pressure and blood sugar, as well as application thereof | |
| US20170360864A1 (en) | Method for increasing expressions of clock gene, arntl gene, and/or per2 gene by using momordica charantia extract | |
| US20190307827A1 (en) | Method for inhibiting expression of icam-1 gene | |
| KR101447121B1 (en) | Composition or health food for xanthine oxidase inhibition containing extract of unripe quince | |
| CN110368417A (en) | Gorgon fruit extract is in the application for inhibiting the performance of ICAM-1 gene | |
| CN111281902A (en) | Application of lithocarpus litseifolius or active extract thereof | |
| US20120003262A1 (en) | Anticancer health food containing phellinus linteus and vegetable worms | |
| CN109045027A (en) | The drug and application for preventing and treating ischemic heart disease or ischemic cerebral disease or thrombosis | |
| TWI689312B (en) | Fermentation product of mung bean hull and uses of the same | |
| CN108201544A (en) | Red goosefoot extract is in the application of regulation and control NOS3, PLAT, F3 and/or SERPINE1 gene performance | |
| US20190142891A1 (en) | Fermentation product of mung bean hull and uses of the same | |
| US10835567B2 (en) | Method for regulating expressions of TPH1 gene, DDC gene, and/or AANAT gene by using banana peel extract | |
| KR102208654B1 (en) | Composition comprising banana peel extract for regulating expressions of tph1 gene, ddc gene and/or aanat gene | |
| US10555984B2 (en) | Method for increasing expression of PDPRD gene by using peanut skin extract | |
| CN106344634B (en) | A kind of mango bark extract and its preparation method and application | |
| JP5362976B2 (en) | Blood flow improver | |
| KR100534066B1 (en) | Mushroom lactic acid fermented solution including effective ingredients for decreasing the value of blood sugar, and method for manufacturing the solution | |
| KR20140072418A (en) | Composition for Improving Obesity | |
| US10675319B2 (en) | Method for regulating circadian clock, regulating diurnal preference, adjusting a biological clock, improving sleep quality and/or facilitating sleep by using momordica charantia extract | |
| KR20130075981A (en) | Composition comprising extract of hot peppers and chinese peppers for preventing or treating of obesity or hyperlipidemia | |
| CN107349192A (en) | Poria cocos skin zone extract, Poria cocos eo-acid A and Poria cocos eo-acid B are in the purposes of regulation blood glucose | |
| KR101963623B1 (en) | A composition for preventing, alleviating or treating inflammatory eye disease comprising Lithospermum erythrorhizon extract | |
| JP3534704B2 (en) | Cholesterol production inhibitor and method for producing the same | |
| CN107296817A (en) | Tuckahoe extract and soil is not sour in the purposes for protecting muscle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191025 |